> Novo Nordisk ($NVO) says it intends to stay in Russia for the "long haul" despite the country's ongoing economic downturn. Report
> Mylan ($MYL) is expanding its hep C licensing agreement with Gilead ($GILD) to include an investigational pan-genotypic prospect. Release
> The U.K.'s cost-effectiveness gatekeeper has approved Alexion's ($ALXN) Soliris in final guidance, making it the first med to pass through the watchdog's new assessment system for highly specialized technologies. Report
> GlaxoSmithKline ($GSK) has rolled out new respiratory treatments Arnuity Ellipta for asthma and Incruse Ellipta for COPD in the U.S. Release
> Purdue Pharma has launched Hysingla ER, a once-daily opioid with abuse-deterrent properties. Release
And Finally... Procter & Gamble's ($PG) ZzzQuil's Twitter feed came under fire last week for a tweet critics called sexist. More